Introduction
============

The symptoms and signs of dry eye disease (DED) may be influenced by the weather, seasons, and other environmental factors.[@b1-opth-11-1769]--[@b4-opth-11-1769] Previous investigations have indicated that different seasons (spring, summer, and winter), cold and hot weather, wind, and sunshine may all exacerbate DED.[@b1-opth-11-1769]--[@b3-opth-11-1769] Air pollen is a seasonal environmental factor[@b3-opth-11-1769] that can induce allergic conjunctivitis, a problem that may be associated with DED.[@b5-opth-11-1769],[@b6-opth-11-1769] A national survey demonstrated a close association between the severity of hay fever and elevated air pollen counts.[@b7-opth-11-1769],[@b8-opth-11-1769] The highest incidence of plant pollution (mostly *Cryptomeria japonica* and *Chamaecyparis obtusa*) and aeolian dust (Kosa)[@b7-opth-11-1769],[@b8-opth-11-1769] also occurs in spring. DED-related tests may also be climate dependent, with one study reporting that the results of DED tests used to assess ocular surface health and tear stability varied depending on the climate.[@b2-opth-11-1769]

Many studies have used questionnaires or coding databases to evaluate the effects different seasons have on DED; however, none have objectively assessed ophthalmic patients who have been recruited over the four seasons. The aim of the present study was to evaluate the effects of each season on the signs and symptoms of DED. Japan has four distinct seasons during which the temperature, humidity, and daylight time markedly varies. It is hot and humid in summer and cold and dry in winter. Between 1981 and 2010, the average temperature and humidity in the Tokyo area ranged from 5.2°C and 52% in winter to 25.0°C and 77% in summer, respectively.[@b9-opth-11-1769] We analyzed corneal findings, tear film function, and DED-related symptoms over 1 year and herein report the differences in the results obtained for each season. Finally, we attempted to demonstrate that DED subtypes could be associated with particular seasons. For example, short break-up time (BUT)-type DED may be more frequent in spring when allergen counts are much higher, and aqueous tear deficiency-type DED may be more frequent in winter when conditions are dry.

Methods
=======

Study participants and institutional review board approval
----------------------------------------------------------

This cross-sectional, case-control study was conducted in Komoro Kosei General Hospital (Nagano, Japan), Shinseikai Toyama Hospital (Toyama, Japan), Tsukuba Central Hospital (Ibaraki, Japan), Jiyugaoka Ekimae Eye Clinic (Tokyo, Japan), Todoroki Eye Clinic (Tokyo, Japan), and Takahashi-Hisashi Eye Clinic (Akita, Japan). The Institutional Review Board and Ethics Committee of Keio University School of Medicine, Komoro Kosei General Hospital, Tsukuba Central Hospital, and Jiyugaoka Ekimae Eye Clinic approved this study, and the methods were carried out in accordance with the Declaration of Helsinki. These hospitals provided ethical approval for the remaining eye clinics, which were classified as collaborators in the ethical documents approved by the hospitals' ethics committees. Informed consent was obtained from all participants.

Inclusion and exclusion criteria
--------------------------------

The present study recruited consecutive patients aged ≥20 years with best corrected visual acuity equal to or better than 20/25 in both the eyes from participating clinics and hospitals between April 2015 and April 2016. Subjects with any acute diseases, cataract, fundus pathology including macular diseases, contact lens wear, history of refractive surgery, punctal occlusion, and punctal plug insertion, all of which may lead to visual and non-visual symptoms, were excluded from the study. To exclude vision disorders that are possibly related to DED symptoms,[@b10-opth-11-1769] patients were excluded if they had severe glaucoma (mean deviation \<−12 dB in either eye), clinically significant cataracts, or bilateral visual impairment (\<20/30 in both eyes).

Ophthalmological examinations
-----------------------------

All outpatients were examined by a board-certified ophthalmologist specializing in cornea services. BUT was measured using a wetted fluorescein filter paper (Ayumi Pharmaceutical Co Ltd, Tokyo, Japan) applied at the lower lid margin. Subjects were instructed to blink three times to ensure adequate mixing of the fluorescein dye with the tear film. The time interval between the third blink and appearance of the first dark spot in the cornea was measured three consecutive times using a stopwatch. The means of the three measurements were regarded as the BUT measurements in this study. The ocular surface was divided into three sections: the nasal conjunctiva, the cornea, and the temporal conjunctiva. Each surface was graded on a scale of 0--3 for severity, and the overall epithelial damage was scored on a scale of 0--9. The Schirmer test was performed without topical anesthesia. Strips of filter paper (Whatman No 41; Showa Yakuhin Kako Co Ltd, Tokyo, Japan) were placed at the outer third of the temporal lower conjunctival fornix for 5 minutes, with the subject spontaneously blinking. The strips were then removed, and the length in millimeters of the filter paper wetted by the spontaneous blinks was recorded. The maximum blinking interval (MBI) was also used to detect and quantify DED as differences in the mean MBI have been reported between non-DED (8.9±4.0 seconds) and DED patients (4.2±2.4 seconds).[@b11-opth-11-1769] The MBI was expressed as the number of seconds the eyes could stay open without blinking.

We used prescription-based classification for analysis in the present study. Patients with no history of treatment and no requirement of DED eyedrop at examination were classified as non-DED. Depending on the severity of DED, patients were prescribed topical medications. We considered DED to be mild if the symptoms and signs could be controlled by hyaluronate alone. Patients with symptoms of dryness and ocular pain that could not be controlled by hyaluronate, and/or with DED signs including persistent epithelial defects and conjunctival injection, were prescribed additional medications and classified as having severe DED. For new patients, participating ophthalmologists determined the prescription of eyedrops mostly by the severity of symptoms, especially in cases with mild signs. Eventually patients with severe DED had steroid and/or mucin secretagogue eyedrops for their severe symptoms. As indicated in previous studies, a prescription-based classification rather than one based on the Japanese Dry Eye Society guidelines[@b12-opth-11-1769] was relevant for the statistical analyses undertaken in this study.[@b13-opth-11-1769],[@b14-opth-11-1769] The criteria of the Japanese Dry Eye Society classifies DED into definite DED (DDED), probable DED (PDED), and non-DED according to the presence of DE symptoms, tear abnormalities (Schirmer test ≤5 mm or BUT ≤5 seconds), and superficial punctate keratopathy (SPK; staining score ≥3). Cases were classified as DDED if all three signs were present, as PDED if two signs were present, and as non-DED if only one sign or no signs were present.

Patient interviews for DED-related symptoms
-------------------------------------------

Patients were asked questions to determine the presence or absence of six common DED-related symptoms, namely dryness, irritation, and pain as non-visual symptoms and, eye fatigue, blurring, and photophobia as visual symptoms. These questions were selected from items in the Dry Eye Questionnaire Score[@b15-opth-11-1769] and were based on the six most prevalent symptoms of DED patients who had visited the Dry Eye Clinic in the Department of Ophthalmology at Keio University Hospital in 2014. We classified eye fatigue, blurring, and photophobia as visual symptoms and dryness, irritation, and pain as non-visual symptoms.

Statistical analysis
--------------------

We first classified the patients into non-DED and DED groups according to prescriptions received for DED and then analyzed each participant's symptoms and signs. The seasons were classified as follows: spring from March to May, summer from June to August, fall from September to November, and winter from December to February. The effects of each season on the symptoms and signs of DED were compared in the following way. First, the percentage of participants presenting with DED symptoms and abnormal test results were determined for every season. Schirmer test and tear BUT test results from the right eye only were used for analysis. Second, from this, we determined the severity of each sign and symptom according to the season. We then compared the season with the least severe results to that with the most severe results for each sign and symptom and used the chi-square test to determine if the differences between these seasons were significant. Data are presented as the mean ± standard deviation (SD) or as percentages where appropriate. All analyses were performed using StatFlex (Atech, Osaka, Japan), with *P*\<0.05 considered significant.

Results
=======

Study participants
------------------

A total of 2,600 outpatients participated in this study, and 684 (26.3%) were diagnosed with DED using a prescription-based classification ([Table 1](#t1-opth-11-1769){ref-type="table"}). The mean age of participants in the non-DED group was 54.4±14.4 years and 42.7% were male. The mean age of participants in the DED group was 56.1±18.1 years and 19.3% were male. More women than men were diagnosed with DED in this study (*P*=0.000, chi-square test), and patients in the DED group were older than those in the non-DED group (*P*=0.047, Mann--Whitney *U* test). A significant seasonal difference was observed for intra-ocular pressure only (*P*=0.002, Kruskal--Wallis test). Most of the participants (62%) were recruited from three eye clinics in the Tokyo metropolitan area and two eye clinics in the mid-Japan area (35%). The remaining participants (3%) were recruited from an eye clinic in the northern area. When the types of eye clinic that participants were recruited from were compared, we found that 48.9% were recruited from general hospitals and eye hospitals and 51.1% from vision care clinics.

Seasonal variation of DED signs and symptoms
--------------------------------------------

[Table 2](#t2-opth-11-1769){ref-type="table"} and [Figures 1](#f1-opth-11-1769){ref-type="fig"} and [2](#f2-opth-11-1769){ref-type="fig"} show the seasonal variation of DED symptoms and signs in the two patient groups. We also compared the season in which each sign and symptom was most severe with the season in which they were least severe ([Table 2](#t2-opth-11-1769){ref-type="table"}; [Figures 1](#f1-opth-11-1769){ref-type="fig"} and [2](#f2-opth-11-1769){ref-type="fig"}). The majority of symptoms were most severe in spring and least severe in summer, and when these seasons were compared in the DED group, significant results were found for irritation (*P*=0.001), pain (*P*=0.007), blurring (*P*=0.000), and photophobia (*P*=0.007, [Figure 1B](#f1-opth-11-1769){ref-type="fig"}), as well as SPK (*P*=0.001) and BUT (*P*=0.000, [Figure 2B](#f2-opth-11-1769){ref-type="fig"}). The overall pattern of seasonal severity was similar for symptoms of pain, fatigue, and photophobia ([Figure 1B](#f1-opth-11-1769){ref-type="fig"}). In contrast, the Schirmer test values were highest in spring and lowest in winter; that is, tear production was greatest in spring and lowest in winter ([Figure 2B](#f2-opth-11-1769){ref-type="fig"}). Seasonal effects were also observed in the non-DED group, with most symptoms and signs being considerably less severe in summer ([Figures 1A](#f1-opth-11-1769){ref-type="fig"} and [2A](#f2-opth-11-1769){ref-type="fig"}). However, the differences in severity between summer, winter, and fall were not as large as those observed in the DED patients.

Discussion
==========

This study demonstrated that many of the signs and symptoms of DED are associated with each season. DED symptoms and signs were generally most severe in spring and least severe in summer for DED patients, indicating that the high temperatures and high humidity in summer may be ideal for DED sufferers. Blurring, photophobia, irritation, BUT, and SPK were most severe during spring; however, there was no significant variation in the severity of these DED signs and symptoms between summer, fall, and winter. This suggests that something may trigger an increase in the severity of DED symptoms and signs in spring such as air-borne pollens. As elevated air pollen counts are directly associated with the severity of hay fever,[@b7-opth-11-1769],[@b8-opth-11-1769] seasonal allergens are expected to be an exacerbating factor for DED. In keeping with our results, the Japan Meteorological Agency reported that the pollen counts in Japan were highest from the beginning of March to the end of April in 2015 and 2016.[@b7-opth-11-1769],[@b8-opth-11-1769] In contrast, we found that the number of participants with a low Schirmer test result was lowest in spring. This suggests that tear production may increase in spring as a scavenging response to an increase in seasonal allergens, demonstrating another link between DED and seasonal allergens. Based on our results, which showed increases in the occurrence of short BUT-type DED in spring and aqueous tear deficiency-type DED in winter, DED subtypes may be subject to seasonal variation. According to a recent review from Asia Dry Eye Society,[@b16-opth-11-1769] BUT and symptoms were recognized as major diagnostic criteria and the importance of visual symptoms was emphasized as a result of unstable tear film. Our results clearly corresponded to this new criterion since seasonal variation of BUT was quite similar to that of visual symptoms including fatigue, blurring, and photophobia.

A number of risk factors and confounding factors can affect the clinical presentation of DED.[@b17-opth-11-1769]--[@b26-opth-11-1769] The severity of DED may be affected by age-dependent tear secretion[@b17-opth-11-1769] diurnal variation of tear secretion and visual function,[@b18-opth-11-1769],[@b19-opth-11-1769] neural regulation,[@b20-opth-11-1769],[@b21-opth-11-1769] sleep deprivation,[@b22-opth-11-1769] blue light exposure,[@b23-opth-11-1769],[@b24-opth-11-1769] eye closure,[@b25-opth-11-1769] and display watching.[@b26-opth-11-1769] In addition, general parameters including smoking, age, sex, LASIK, connective tissue disease, and medications including anti-cholinergics[@b27-opth-11-1769]--[@b29-opth-11-1769] may also affect the severity of DED. Indeed, our results showed that women were more likely to have DED than men, which is consistent with previous reports.[@b30-opth-11-1769]--[@b32-opth-11-1769] The effects of hormones and hormone replacement therapy on DED and climacteric symptoms[@b33-opth-11-1769],[@b34-opth-11-1769] have been investigated; however, the results are inconclusive. DED affects happiness,[@b35-opth-11-1769] quality of life,[@b36-opth-11-1769],[@b37-opth-11-1769] and sleep.[@b14-opth-11-1769],[@b38-opth-11-1769]--[@b41-opth-11-1769] It is also closely associated with depression.[@b41-opth-11-1769] Due to its high prevalence and these considerable impacts on health and productivity,[@b42-opth-11-1769] a better understanding of DED is critical for the general population and health professionals.

Various diagnostic criteria, different seasons, and differing clinic practices may greatly contribute to the statistical variations observed in clinical DED research. The present study has strived to be well designed and has analyzed a sufficient sample size. Patients from both hospitals and vision care clinics were recruited over a 1-year period by direct interviews and physicians' examinations. We endeavored to maintain the homogeneity of the data set even though patients were recruited from various ophthalmic practices and locations by ensuring that the same criteria were used by all participating institutes. We found that the prevalence and severity of DED was greater in patients who visited vision care clinics in the Tokyo metropolitan area compared with those who visited hospitals in other regions of Japan (data not shown). This finding is consistent with the results of another investigation.[@b30-opth-11-1769] It is possible that this is because individuals with undiagnosed DED find it difficult to visit hospitals since most hospital services require reservations or a referral letter and have limited registration hours. In contrast, vision care clinics are much more accessible. We are currently working to resolve this topic.

Limitations
===========

We would like to emphasize several limitations of our study. First, we did not exclude glaucoma, early cataract, or pseudophakic patients, even though these comorbidities may affect the symptoms and signs of DED. Second, DED itself is a multifactorial disease with many possible confounding factors that may potentially be affected by seasonal variations, including systemic and psychiatric comorbidities, medications, and ocular complications. We did not check the participants' detailed medical histories due to time and space limitations in the participating institutions. Third, the self-reported symptoms of DED are subject to reporting bias, as there is variation in how different individuals experience symptoms of pain, irritation, and sensitivity. The results of this study should be confirmed further using a comprehensive DED classification such as the one proposed by the 2007 Dry Eye Workshop,[@b43-opth-11-1769] although our results were consistent with diagnostic criteria of Asia Dry Eye Society.[@b16-opth-11-1769]

Conclusion
==========

In conclusion, the present results indicate that patients with DED may suffer most seriously in spring. Our findings also demonstrate that DED subtypes can be subject to seasonal variation. We found an increase in cases of short BUT-type DED in spring, possibly due to elevated air pollen counts.
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![Presence of DED-related symptoms in (**A**) non-DED and (**B**) DED patients. Seasonal variation was observed for irritation, pain, blurring, and photophobia in DED patients, with symptoms being most severe in spring. Seasonal variation was also observed in the non-DED subjects, with symptoms being least severe in summer. There was no significant variation in the severity of symptoms between summer, fall, and winter in the non-DED subjects. ^\*^*P*\<0.05 when the season with the most severe symptoms was compared to the season with the least severe symptoms (chi-square test).\
**Abbreviation:** DED, dry eye disease.](opth-11-1769Fig1){#f1-opth-11-1769}

![Presence of DED-related signs in (**A**) non-DED and (**B**) DED patients. Seasonal variation was observed in BUT and SPK in the DED patients. Seasonal variation in all signs except for the Schirmer test was observed in the non-DED subjects. ^\*^*P*\<0.05 when the season with the most severe symptoms was compared to the season with the least severe symptoms (chi-square test).\
**Abbreviations:** BUT, tear break-up time; DED, dry eye disease; MBI, maximum blinking interval; SPK, superficial punctuate keratitis.](opth-11-1769Fig2){#f2-opth-11-1769}

###### 

Patient characteristics

  Diagnostic group                                                          Non-DED[A](#tfn1-opth-11-1769){ref-type="table-fn"}   DED[A](#tfn1-opth-11-1769){ref-type="table-fn"}   *P*-value[\*](#tfn3-opth-11-1769){ref-type="table-fn"}                                       
  ------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------- -------------------------------------------------------- ----------- ----------- ----------- ----------------------------------------------------
  Number of patients (n)                                                    1,916                                                 143                                               143                                                      229         169         684         
  \% male                                                                   42.7                                                  18.2                                              21.7                                                     16.6        21.9        19.3        0.697
  Age (years)[B](#tfn2-opth-11-1769){ref-type="table-fn"}                   54.4±14.4                                             54.4±16.5                                         56.7±15.5                                                57.6±16.8   54.9±15.1   56.1±18.1   0.219
   Median                                                                   56                                                    56                                                58                                                       62          55          57          
   Range                                                                    20--92                                                20--89                                            21--88                                                   20--91      20--94      20--94      
  High myopia (≤−6.00 D) (%)                                                15.9                                                  14.4                                              9.6                                                      14.6        17.0        14.0        0.532
  Bilateral pseudophakia (%)                                                7.7                                                   6.3                                               2.8                                                      8.2         13.2        7.7         0.056
  Intraocular pressure (mmHg)[B](#tfn2-opth-11-1769){ref-type="table-fn"}   14.0±3.1                                              14.5±3.0                                          14.4±3.0                                                 14.1±2.9    15.4±3.9    14.6±3.2    0.002[\*](#tfn3-opth-11-1769){ref-type="table-fn"}
  Topical glaucoma medication (%)                                           7.7                                                   7.0                                               5.7                                                      8.8         13.9        8.9         0.200
  Topical DED medication (%)                                                                                                                                                                                                                                                     
   Hyaluronate                                                              0                                                     51.7                                              49.7                                                     50.4        64.6        53.5        0.107
   Mucin secretagogue                                                       0                                                     32.9                                              33.6                                                     39.4        25.7        33.9        0.164
   Steroid                                                                  0                                                     14.8                                              16.8                                                     10.2        9.7         12.6        0.245

**Notes:**

Classified as DED or non-DED according to the prescription.

Mean ± SD.

*P*\<0.05, Kruskal--Wallis test or chi-square test as appropriate for comparing the 4 seasons.

**Abbreviation:** DED, dry eye disease.

###### 

Seasonal variations in DED signs and symptoms

  Recruitment season         Non-DED[A](#tfn5-opth-11-1769){ref-type="table-fn"}   DED[A](#tfn5-opth-11-1769){ref-type="table-fn"}   Seasonal severity of DED symptoms and signs                                                       
  -------------------------- ----------------------------------------------------- ------------------------------------------------- --------------------------------------------- ---------------- ---------------- -------- -------- -------
  PDED and DDED              --                                                    71.3 (102/143)                                    51.0 (73/143)                                 66.1 (151/229)   70.8 (120/169)   Summer   Spring   0.000
  DDED                       --                                                    11.2 (16/143)                                     9.2 (13/143)                                  12.8 (29/229)    9.4 (16/169)     Summer   Fall     0.104
  Signs                                                                                                                                                                                                                                
   SPK (staining score ≥3)   6.1 (117/1,916)                                       29.4 (42/143)                                     13.3 (19/143)                                 15.7 (36/229)    22.2 (36/169)    Summer   Spring   0.001
   Schirmer test (≤5 mm)     19.0 (23/122)                                         17.1 (6/35)                                       27.9 (17/61)                                  21.4 (8/39)      41.2 (8/20)      Spring   Winter   0.061
   BUT (≤5 s)                42.6 (812/1,907)                                      73.9 (105/142)                                    52.4 (75/143)                                 58.3 (134/229)   63.6 (105/168)   Summer   Spring   0.000
   MBI (≤9 s)                25.7 (488/1,900)                                      30.0 (39/130)                                     41.5 (59/142)                                 35.4 (84/229)    35.4 (57/169)    Spring   Summer   0.013
  Symptoms                                                                                                                                                                                                                             
   Dryness                   21.8 (417/1,915)                                      42.0 (60/143)                                     51.0 (73/143)                                 54.3 (121/223)   52.8 (89/169)    Summer   Fall     0.113
   Irritation                13.8 (264/1,911)                                      37.1 (53/143)                                     20.3 (28/138)                                 30.4 (70/229)    24.3 (41/169)    Summer   Spring   0.001
   Pain                      4.6 (50/1,911)                                        12.6 (18/143)                                     7.1 (10/141)                                  15.4 (35/229)    12.5 (21/169)    Summer   Fall     0.007
   Fatigue                   28.1 (538/1,915)                                      47.6 (68/143)                                     44.1 (63/143)                                 43.5 (98/225)    54.2 (90/166)    Fall     Winter   0.105
   Blurring                  14.6 (279/1,911)                                      38.5 (55/143)                                     7.2 (10/141)                                  17.0 (37/218)    28.5 (47/165)    Summer   Spring   0.000
   Photophobia               13.9 (266/1,911)                                      25.2 (36/143)                                     13.1 (18/137)                                 21.3 (48/225)    23.6 (40/169)    Summer   Spring   0.007

**Notes:**

Prescription-based classification. Data are presented as percentages, with n values (number of positive subjects/number of examined subjects) in parentheses.

Chi-square test.

**Abbreviations:** BUT, tear break-up time; DDED, definite DED; DED, dry eye disease; MBI, maximum blinking interval; PDED, probable DED; SPK, superficial punctuate keratitis.
